logo-loader

Cardiol Therapeutics files patent to use CBD therapies for patients with coronavirus

Research shows that cannabidiol could reduce the severity and prevent the progression of COVID-19 symptoms in patients with pre-existing cardiovascular conditions

Cardiol Therapeutics -
There is growing evidence that patients with COVID-19 are at a higher risk of developing cardiovascular complications

Cardiol Therapeutics Inc (TSE:CRDL) (OTCQX:CRTPF) has filed a new patent application to cover the use of cannabidiol in patients with COVID-19, the disease caused by coronavirus.

Cannabidiol, or CBD, could reduce the severity and prevent the progression of COVID-19 symptoms in patients with pre-existing cardiovascular conditions, according to Cardiol.

The Oakville-based company is developing CBD-based therapies for heart disease as well as proprietary nanotechnology to deliver pharmaceutical cannabidiol directly into sites of inflammation in the heart.

READ: Cardiol Therapeutics says its nanotechnology successfully delivers anti-fibrotic drugs to diseased heart

While coronavirus attacks the respiratory system, there is growing evidence that patients with COVID-19 are at a higher risk of developing cardiovascular complications, Cardiol said in a statement.

What’s more, people with pre-existing cardiovascular disease are more likely to develop severe symptoms associated with COVID-19 and could suffer a worse prognosis than their healthy peers. According to a recent study published in the Journal of the American Medical Association Cardiology, 35% of patients hospitalized with COVID-19 had underlying cardiovascular disease and had a significantly higher mortality rate than patients without heart conditions.

David Elsley, Cardiol’s CEO, told investors that the company is looking at how its CBD formulation could help COVID-19 patients with cardiovascular disease.

"Experimental evidence demonstrating the cardioprotective properties of cannabidiol suggest therapeutic potential in this vulnerable patient population,” Elsley said in a statement.

“As part of our strategy to develop cannabidiol for patients with heart failure, we look forward to investigating the anti-inflammatory properties of our extra strength CBD formulation in COVID-19 patients with cardiac injury, with the hope of significantly improving patient outcomes."

Pre-clinical research looks promising. In a model involving cardiac injury, Cardiol's pharmaceutically-produced cannabidiol had a cardioprotective effect that led to a reduction of fibrosis, cardiac hypertrophy, and the cardiac remodeling marker BNP.

Data from the research was presented at the American College of Cardiology's 69th Annual Scientific Session & Expo, held virtually at the end of March.

Shares in Toronto added 4.64% to C$3.16.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Protech Home Medical has a full treasury as they look for rapid growth in...

Protech Home Medical (CVE: PTQ- OTCQX: PTQQF) CEO Greg Crawford joined Steve Darling from Proactive to discuss the home medical equipment industry company. That company provides devices like ventilators and oxygen concentrators. Crawford told Proactive the company just completed a large...

21 hours, 6 minutes ago

2 min read